| Ytd | -8.80% | |
| 1y | 7.70% |
| Open | 19.45 | Prev Close | 19.45 | Low | 19.45 | High | 20.20 | Mkt Cap | 758.85M |
| Vol | 316.59K | Avg Vol | 318.85K | EPS | -1.62 | P/E | N/A | Forward P/E | -24.29 |
| Beta | N/A | Short Ratio | 2.68 | Inst. Own | 39.53% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-04 | 50-d Avg | 18.92 | 200-d Avg | 17.79 | 1yr Est | 33.25 |
CBLL News
CeriBell, Inc. (NASDAQ:CBLL) ("Ceribell"), a medical technology company focused on transform
Canaccord Genuity analyst William Plovanic maintains CeriBell (NASDAQ:CBLL) with a Buy and lowers
CeriBell (NASDAQ:CBLL) raises FY2026 sales outlook from $111.000 million-$115.000 million to $112.00
CeriBell (NASDAQ:CBLL) reported quarterly losses of $(0.52) per share which missed the analyst conse
CeriBell (NASDAQ:CBLL) reported quarterly losses of $(0.36) per share which beat the analyst consens
Canaccord Genuity analyst William Plovanic maintains CeriBell (NASDAQ:CBLL) with a Buy and raises
CeriBell, Inc. (Nasdaq: CBLL) ("Ceribell"), a medical technology company focused on transfor
JP Morgan analyst Robbie Marcus maintains CeriBell (NASDAQ:CBLL) with a Overweight and lowers the
TD Cowen analyst Joshua Jennings maintains CeriBell (NASDAQ:CBLL) with a Buy and lowers the price
2025 Financial OutlookCeribell is raising its revenue guidance for the full year 2025 to a range of
CeriBell (NASDAQ:CBLL) reported quarterly losses of $(0.37) per share which beat the analyst consens
Raymond James analyst Jayson Bedford initiates coverage on CeriBell (NASDAQ:CBLL) with a Strong B
CeriBell (NASDAQ:CBLL) reported quarterly losses of $(0.38) per share which beat the analyst consens
CeriBell (NASDAQ:CBLL) raises FY2025 sales outlook from $83.000 million-$87.000 million to $85.000 m
Shares of MicroStrategy Incorporated (NASDAQ:MSTR) rose sharply in today's pre-market trading.